COMMUNIQUÉS West-GlobeNewswire

Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne
10/06/2026
L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie musculaire de Duchenne [...]
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
10/06/2026
New solution integrates speech recognition, clinical AI findings, measurements, AI-generated impressions and quality assurance SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI [...]
Reacta Healthcare Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate
10/06/2026
DEESIDE, United Kingdom, June 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces [...]
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
10/06/2026
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany NEUMÜNSTER, Germany, June 10, 2026 (GLOBE NEWSWIRE) -- [...]
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
10/06/2026
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD community NDS is based on Italfarmaco’s Phase 3 EPIDYS trial data [...]
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
10/06/2026
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 . Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical [...]
China's Leading Brand CUKTECH has Cumulatively Sold Over 150 Million Power Banks Globally, Taking a Further Step Towards Globalization
10/06/2026
CANBERRA, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Latest data from CUKTECH, a leading Chinese brand, shows that it has cumulatively shipped over 150 million power banks and 20 million chargers. As technology [...]
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
10/06/2026
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI [...]
Vara receives CE mark for tomosynthesis AI - extending Europe’s leading screening-grade AI portfolio to 3D
10/06/2026
BERLIN, June 10, 2026 (GLOBE NEWSWIRE) -- Vara, the AI company powering more than half of Germany’s organized breast cancer screening program, today received CE class 2b marking under EU MDR for its tomosynthesis (3D [...]
IBA Announces Research Collaboration to Strengthen Evidence on the Value of Proton Therapy
10/06/2026
Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer [...]
Communiqué de presse : Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire démyélinisante chronique
10/06/2026
Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire démyélinisante chronique Paris, le 10 juin 2026. Sanofi a annoncé aujourd’hui que l’étude de phase 3 [...]
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
10/06/2026
Dr Hirawat i s the former CMO and Head of Global Drug Development at Bristol Myers Squibb and former EVP and Head of Oncology Development at Novartis Augments Cytospire’s clinical development experience as Cytospire [...]
IBA annonce une collaboration de recherche visant à renforcer les preuves sur la valeur de la protonthérapie
10/06/2026
Louvain-la-Neuve, Belgique, le 10 juin 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de protonthérapie pour [...]
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
10/06/2026
Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted [...]
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
10/06/2026
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer [...]
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
10/06/2026
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first- [...]
ARCPOINT ANNOUNCES APPOINTMENT OF PETER KENDALL AS INTERIM CHIEF EXECUTIVE OFFICER
10/06/2026
GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer [...]
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
10/06/2026
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the [...]
TerrAscend Announces Results of Annual General Meeting
09/06/2026
TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis operator, today announced the results of its annual meeting of [...]

Pages